Latest Breaking News On - Research at pharmala biotech - Page 1 : comparemela.com

Patent Allowance Granted for ALA-002 Composition by US Patent and Trademark Office

Novel Composition of MDMA Enantiomers leading to next-generation MDMA possibilitiesTORONTO, March 27, 2024 PharmAla Biotech Holdings Inc. , a biotechnology company focused on the research,.

New south walesNicholas kadyshHarpreet kaurNick kadyshTrademark officeRegulation services providerPharmala biotech holdings incNeither the canadian securities exchangeDrug administrationUniversity of sydneyResearch at pharmala biotechNovel compositionAla biotech holdingsChemical entityGeneral populationVice president

PharmAla named an Intellectual Property Ontario Client

PharmAla named an Intellectual Property Ontario Client
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Province of ontarioUnited kingdomBritish columbiaHarpreet kaurNicholas kadyshchief executive officerpharmala biotech holdings incNeither the canadian securities exchangeUniversity of windsorRegulation services providerResearch at pharmala biotechPharmala biotech holdings incInternational society for researchAla biotech holdingsIntellectual property ontarioInternational societyCanadian securities exchange

PharmAla Data to be Published in ACS Chemical Neuroscience

Scientific Journal Article follows notable IP updates, including publication of key PCT Patent Application, presentation at International Society for Research into Psychedelics ConferenceVANCOUVER, British Columbia, Feb. 20, 2024 (GLOBE NEWSWIRE) PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased that

United statesNew orleansBritish columbiaUnited kingdomHarpreet kaurNick kadyshNicholas kadyshWilliam fantegrossiJames gauldA path to novel mental health therapiesNeither the canadian securities exchangeUniversity of waterlooPharmala biotech holdings incInternational society for researchUniversity of arkansasRegulation services provider

USFDA Approves LaNeo MDMA for Clinical Trial Use in the United States

USFDA Approves LaNeo MDMA for Clinical Trial Use in the United States
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesBritish columbiaHarpreet kaurDavid purcellNick kadyshRegulation services providerHealth canadaResearch at pharmala biotechDrug administrationPharmala biotech holdings incNeither the canadian securities exchangePrescriber programVitura healthNicholas kadyshchief executive officerpharmala biotech holdings incApproved study

USFDA Approves LaNeo MDMA for Clinical Trial Use in the

Approved Study to Examine Tolerability of MDMA in Schizophrenia at UCLA VANCOUVER, British Columbia, June 09, 2023 (GLOBE NEWSWIRE) PharmAla Biotech.

United kingdomUnited statesBritish columbiaHarpreet kaurNicholas kadyshDavid purcellNick kadyshHealth canadaDrug administrationResearch at pharmala biotechRegulation services providerNeither the canadian securities exchangeVitura healthPrescriber programPharmala biotech holdings incApproved study